Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Dendritic cell targeted affinity peptide TY peptide and application thereof

A dendritic cell and targeting technology, applied in the field of protein-related tumor therapy, can solve the problems of CTL incompetence, low antigen transport efficiency, weak ability to stimulate anti-tumor immune response, etc.

Active Publication Date: 2018-12-18
ZHENGZHOU UNIV
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the preliminary application shows that the existing tumor vaccines have the defects of weak ability to stimulate anti-tumor immune response, the main reasons are low antigen transport efficiency, fast degradation rate in vivo, weak antigen cross-presentation ability, and most of them are delivered by non-professional antigens. The recognition of cells causes off-target effects of antigens, which in turn induces the incompetence of CTLs, thereby weakening the effect of treating tumors. Therefore, it is of great significance to screen new targeting DC molecules and design new tumor vaccines to improve the therapeutic effect of tumor vaccines.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Dendritic cell targeted affinity peptide TY peptide and application thereof
  • Dendritic cell targeted affinity peptide TY peptide and application thereof
  • Dendritic cell targeted affinity peptide TY peptide and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] The affinity peptide TY peptide targeting dendritic cells provided in this application was screened by phage display peptide library technology, and the screening process included sorting mouse spleen DC cells, panning at the cell level, phage amplification, and affinity DC Steps such as determination of phage monoclonal DNA sequence, etc., this embodiment briefly introduces the specific screening process as follows.

[0042] (1) Sorting mouse spleen DC cells

[0043] Select 6-8 week old C57BL / 6J mice, kill and disinfect (soak in 75% alcohol for about 5 minutes), and prepare DC cells according to the existing technology, or refer to the following operations for details:

[0044] (1) After dissecting the mouse, take out the spleen and cut it into small pieces, add collagenase Ⅰ and DNA Ⅳ enzyme to digest the spleen cells, shake and digest at 37°C for 30 min;

[0045] (2) Grind splenocytes with glass slides, filter with a 70-mesh filter to make a single-cell suspension, ...

Embodiment 2

[0064] Based on the screening of TY peptide obtained in Example 1, the inventors synthesized DC's affinity peptide TY peptide using Fmoc solid-phase synthesis technology. It should be noted that when verifying the affinity of the synthesized TY peptide to DC, a method of indirectly reflecting the affinity of the peptide to DC was obtained by combining fluorescent streptavidin with biotin. After the TY peptide is synthesized, a biotin is further connected to the carboxyl terminal of the TY peptide through a linker-GGG-. In order to facilitate the preparation of subsequent nanocarriers, acetylated TY peptide and antigenic peptide OVA were simultaneously prepared. 257-264 . This embodiment briefly introduces the relevant preparation process as follows.

[0065] (1) Add the first amino acid

[0066] Weigh 0.37 g Rink resin and pour it into the synthesizer, add DMF to make the resin swell for about 30 minutes (if Wang resin is used, do not deprotect); add the prepared deprotecti...

Embodiment 3

[0082] In the actual use of the screened TY peptide, it is limited by biological absorption and biodegradation. Therefore, this application uses the nanomaterial MSN (mesoporous silica nanoparticle) as a carrier to prepare a new type of nanoparticle that can target DC. Vaccine delivery system MSN-TY / OVA / CpG. During the preparation, the acetylated TY peptide was firstly covalently coupled to the surface of MSN by condensation reaction to synthesize MSN-TY, and then the mode antigen OVA and immune adjuvant CpG (CpG-ODN1826) were loaded by electrostatic adsorption.

[0083] The specific process of preparing MSN-TY (the connection of MSN-NH2 and COOH-peptide-Ac) is as follows:

[0084] Dissolve an appropriate amount of acetylated TY peptide in 2 mL of DMF, then add 10 times the equivalent of HoBt to mix and incubate, then add 10 times the equivalent of DIC, mix well with the above reactants, and incubate at room temperature for 10 min to activate the TY peptide. carboxyl;

[008...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
The average particle sizeaaaaaaaaaa
Login to View More

Abstract

Belonging to the tumor therapy protein related technical field, the invention specifically relates to a dendritic cell (DC) targeted affinity peptide TY peptide and application thereof. The TY peptideis 12 peptide, and the specific amino acid sequence is TITHFQFGPTVY. Based on the TY peptide, the invention further designs a novel nano-transportation system capable of targeting DC on the basis ofMSN, and loads the model antigen OVA and immunoadjuvant CpG to prepare the nano-carrier MSN(mesoporous silica nanoparticles)-TY / OVA / CpG successfully. Experiments indicate that: the MSN-TY / OVA / CpG canbe effectively ingested by immature DC, thus improving the efficiency of antigen ingestion by DC, promoting the maturation of DC and effectively activating DC, also effectively promoting antigen processing and presentation, stimulating secretion of cytokines, and further triggering antigen-specific CTL immunoreaction and anti-tumor immunoreaction.

Description

technical field [0001] This application belongs to the technical field related to protein for tumor therapy, and specifically relates to an affinity peptide TY peptide targeting dendritic cells and its application patent application matters. Background technique [0002] Tumors are a serious threat to human health. There are tens of millions of new cases and deaths every year in the world, of which my country accounts for about a quarter. Surgical treatment, radiotherapy and chemotherapy are routine methods for clinical treatment of tumors. Among them, the main problem faced by tumor treatment is late tumor metastasis and high recurrence rate; chemotherapy and radiotherapy have relatively high toxic and side effects, and the treated tumor is prone to develop resistance. Therefore, the development of highly efficient, specific, and low-toxic drugs is an urgent task for tumor treatment. [0003] Tumor immunotherapy makes full use of the activation mechanism of the body's own...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K7/08A61K9/14A61K47/42A61K47/04A61K39/39A61P35/00
CPCA61K9/143A61K9/146A61K39/39A61K2039/55561A61P35/00C07K7/08
Inventor 陈真真刘娅婷高艳锋姚琳通刘雅静
Owner ZHENGZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com